Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LY3873862 in Healthy Participants
NCT05492201Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Aug 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3873862 in amyotrophic lateral sclerosis (ALS) (6 arms), sponsored by Eli Lilly and Company. Primary endpoint: Treatment Emergent Adverse Events. Started Aug 2022; status: completed.
02
Drugs
LY3873862
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05492201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05492201.